The ceiling is recovery, not effort.
A high-scrutiny compounded IGF-1 LR3 prescription for athletes treating recovery capacity as a serious clinical question.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
The limiter nobody trains.
Every serious training week has a hidden number: how many genuinely hard sessions you can absorb before the next one starts borrowing from the one after it. Most people try to raise that number by pushing harder. That works until recovery, not motivation, becomes the thing setting the ceiling.
IGF-1 LR3 belongs in that between-session conversation.
Growth hormone tells the liver to produce IGF-1, and IGF-1 is the signal that reaches muscle and connective tissue and tells them to grow. Most circulating IGF-1 is bound to carrier proteins. LR3 is modified around that constraint.
Research found LR3 substantially more potent than ordinary IGF-1 in cells that produce binding proteins, but less potent in cells that do not.1 The advantage points to reduced binding-protein capture rather than a stronger grip on the receptor. Research also found that LR3 clears from blood considerably faster than ordinary IGF-1, not slower.2
That is what makes the molecule worth considering. It is not a promise that three hard training days become five, but a different biological target for the part of performance that happens after the session ends.
Dose, duration, and follow-up stay inside a clinician-led plan built around your training context and medical history.
For the athlete who knows exactly where recovery breaks first.
Three Hard Days, Not Five
You know the exact point in the week when high-quality work starts turning into accumulated fatigue. Your willingness to train has not changed. The number of sessions you can truly absorb has.
Monday Follows You Into Wednesday
The workout that once cost a day now costs two. You are not asking for more motivation. You are asking why the recovery bill keeps getting larger.
The Deload Arrives Before the Program Says It Should
The plan calls for six weeks. Your body starts negotiating at three. You want to look at the biology between training blocks instead of finding another way to push through it.
Compounded IGF-1 LR3 is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
- Diabetes, prediabetes, or any medication that lowers blood sugar, without clearance from the clinician managing it
- A history of low blood sugar episodes
- Competing in a tested sport, unless you have confirmed the position with your governing body
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
IGF-1 LR3 (Performance), prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- A modified form of the IGF-1 signal, compounded to your individual prescription by a licensed US pharmacy
- A licensed provider reviews your training load, medical history, medications, and full plan before prescribing
- Dose and duration are individualized, with follow-up built into the plan
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Performance.
Wolverine Stack
Two repair pathways. One prescription.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
CJC-1295 / Ipamorelin (Performance)
Not a pre-workout. An upstream signal.
A compounded upstream signaling prescription for people treating recovery capacity as part of performance.
Do not use if you have
- Active or suspected malignancy
Serious risks
- Low blood sugar, the most immediate risk: IGF-1 acts on the same receptor family as insulin
- Sustained use suppresses your own growth hormone and IGF-1 production
- IGF-1 signaling drives cell growth generally, which means any history of cancer requires oncology clearance
- Prohibited at all times by the World Anti-Doping Agency, in and out of competition
This one carries real risk and the screening is not a formality. That is why your provider sets timing around food, and why any diabetes diagnosis or glucose-lowering medication has to be on your intake. Duration is planned rather than open-ended. Human safety data for this analogue is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Human trials have not established muscle growth from IGF-1 LR3 in healthy adults. IGF-1 is a growth signal, LR3 interacts differently with binding proteins, and the potency difference in the cited cell systems tracks with that biology.1 Your clinician evaluates what the treatment does in your case from your actual response.
IGF-1 is an approved medicine in the United States, prescribed as Increlex for people whose bodies do not produce enough of it on their own. IGF-1 LR3 is a modified form of that same signal, built to stay free in the blood rather than bound up by carrier proteins. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
There is no honest universal timeline for a performance-recovery question like this. Your provider sets expectations from your training load, history, baseline, and what actually happens after treatment begins.
A molecule this close to fundamental growth signaling should make the care around it more important, not less. Here, a licensed provider decides whether IGF-1 LR3 belongs in your plan and a licensed US pharmacy compounds it to an individual prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. AnthologyRX+ gives you medical accountability around the molecule, not permission to self-direct a growth signal because the marketing sounded convincing.
Any time, before your renewal date. No phone calls required.
- Francis GL, et al. Novel recombinant fusion protein analogues of insulin-like growth… J Mol Endocrinol. 1992.PubMed
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.